The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization

Current Opinion in Cardiology

Volumn 30, Issue 5, 2015, Pages 525-535

  Banerjee, Subhash ^a   Sarode, Karan ^a   Vinas, Ariel ^b   Banerjee, Avantika ^a   Mohammad, Atif ^a,b   Brilakis, Emmanouil S ^a,b  

^a Veterans Affairs North Texas Health Care System   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Antiplatelet therapy; Endovascular revascularization; Peripheral artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PRASUGREL; TICAGRELOR; VORAPAXAR;

ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONSENSUS; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; LEG REVASCULARIZATION; LIMB ISCHEMIA; META ANALYSIS (TOPIC); MONOTHERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; CLASSIFICATION; COMPLICATION; DISEASE MANAGEMENT; ENDOVASCULAR SURGERY; LOWER LIMB; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; RISK ASSESSMENT; THROMBOSIS; VASCULARIZATION;

DISEASE MANAGEMENT; ENDOVASCULAR PROCEDURES; HUMANS; LOWER EXTREMITY; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOSIS;

EID: 84942566937     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000208     Document Type: Review

References (64)

1. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317-1324.
2. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297:1197-1206.
3. McDermott MM, Hahn EA, Greenland P, et al. Atheroscleroti c risk factor reduction in peripheral arterial diseasea: results of a national physician survey. J Gen Intern Med 2002; 17:895-904.
4. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondar y prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2):e637S-668S.
5. Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124:2458-2473.
6. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the manageme nt of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58:2020-2045.
7. Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S-e690S.
8. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008; 51:1829-1843.
9. Eikelboom JW, Hankey GJ, Thom J, et al. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover tri al. J Thromb Haemost 2005; 3:2649-2655.
10. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30:1964-1977.
11. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Phar macol 2007; 63:421-430.
12. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121:171-179.
13. Chackalamannil S, Xia Y, Greenlee WJ, et al. Di scovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 2005; 48:5884-5887.
14. Antithrombotic Trialists Collaboration. Aspiri n in the primary and secondary prevention of vascular disease: collaborative meta-Analysis of individual participant data from randomised trials Lancet 2009 373 1849-1860.
15. Banerjee S, Vinas A, Moham mad A, et al. Significance of an abnormal anklebrachial index in patients with established coronary artery disease with and without associated diabetes mellitus. Am J Cardiol 2014; 113:1280-1284.
16. Di ehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 2009; 120:2053-2061.
17. Norgre n L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S):S5-S67.
18. Berger JS, Krantz MJ, Ki ttelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a metaanalysis of randomized trials. JAMA 2009; 301:1909-1919.
19. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303:841-848.
20. Catalano M, Born G, Peto R, et al. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, doubleblind trial. J Intern Med 2007; 26 1:276-284.
21. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.
22. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral a rtery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011; 124:17-23.
23. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329-1339.
24. Neri Serneri GG, Coccheri S, Marubini E, et al. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur Heart J 2004; 25:1845-1852.
25. Bossavy JP, Thalamas C, Sagnard L, et al. A dou ble-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92:1518-1525.
26. Moshfegh K, Red ondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36:699-705.
27. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
28. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
29. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49:1982-1988.
30. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-cont rolled trial. Lancet 2004; 364:331-337.
31. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366:1404-1413.
32. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA28P-TIMI 50. Circulation 2013; 127:1522-1529; 9e1-6.
33. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
34. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001-2015.
35. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-1057.
36. Sarode K, Mohammad A, Das S, et al. Compar ison of dual antiplatelet therapy durations after endovascular revascularization of infrainguinal arteries. Ann Vasc Surg 2015; doi: 10.1016/j.avsg.2015.03.040. [Epub ahead of print] Demonstrates equipoise in prescription of dual antiplatelet th erapy among patients following endovascular revascularization for symptomatic PAD.
37. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenousvein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie N Engl J Med 1997 337 1726-1731.
38. Minar E, Ahmadi A, Koppensteiner R, et al. Comparison of effects of high-dose an d low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty. Circulation 1995; 91:2167-2173.
39. Tepe G, Bantleon R, Brechtel K, et al. Management of peripheral a rterial interventions with mono or dual antiplatelet therapy: the MIRROR study-A randomised and double-blinded clinical trial. Eur Radiol 2012; 22:1998-2006.
40. Belch JJ, Dormandy J, Committee CW, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52:825-833; 33 e1-2.
41. Burdess A, Nimmo AF, Garden OJ, et al. Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia. Ann Surg 2010; 252:37-42.
42. Armstrong EJ, Anderson DR, Yeo KK, et al. Association of dual antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg 2015; 62:157-1 65. Observational data demonstrating a reduction in major adverse cardiovascular events in patients undergoing angiography or endovascular revascularization for symptomatic PAD.
43. Das S, Mohammad A, Spelber DA, et al. Optimal dual antiplatelet therapy after lower extremity revascularization. Catheterization and Cardiovascular intervention; Vol. 83, p.S84; 1 May 2014.
44. Antiplatelet Strategy for Peripheral Arterial Interventions for Revascula rization of Lower Extremities (ASPIRE). [Accessed on 19 December 2014, at https://clinicaltrials.gov/ct2/show/NCT02217501.].
45. Sarode K, Spelber DA, Bhatt DL, et al. Drug delivering technology for endovascu lar management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv 2014; 7:827-839. Review article that highlights the emerging drug delivering technologies available for use in endovascular revascularization for patie nts with PAD, which may have implications regarding optimal antiplatelet therapy.
46. Brodmann M, Rief P, Froehlich H, et al. Neointimal hyperplasia after silverhawk atherectomy versus percutaneous transluminal angiop lasty (PTA) in femoropopliteal stent reobstructions: a controlled, randomized pilot trial. Cardiovasc Intervent Radiol 2013; 36:69-74.
47. Diaz ML, Urtasun F, Barberena J, et al. Cryoplasty versus conventional angioplasty in femoropopliteal arterial recanalization: 3-year analysis of reintervention-free survival by treatment received. Cardiovasc Inter vent Radiol 2011; 34:911-917.
48. Jahnke T, Mueller-Huelsbeck S, Charalambous N, et al. Prospective, randomized single-center trial to compare cryoplasty versus conventional angioplasty in the poplit eal artery: midterm results of the COLD study. J Vasc Interv Radiol 2010; 21:186-194.
49. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous translumi nal angioplasty in superficial femoral artery lesions up to 10cm in length: the femoral artery stenting trial (FAST). Circulation 2007; 116:285-292.
50. Laird JR, Katzen BT, Scheinert D, et al. N itinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010; 3:267-276.
51. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007; 115:2745-2749.
52. Zeller T, Tiefenbacher C, Steinkamp HJ, et al. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). J Endovasc Ther 2008; 15:390-398.
53. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg 2012; 55:390-398.
54. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver P TX randomized and single-Arm clinical studies. J Am Coll Cardiol 2013; 61:2417-2427.
55. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atheroscle rotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006; 13:701-710.
56. Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol 2012; 60:229 0-2295.
57. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv 2013; 6:1295-1302.
58. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008; 358:689-699.
59. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIE R trial. Circ Cardiovasc Interv 2012; 5:831-840.
60. Werk M,Langner S,Reinkensmeier B,et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon-femoral paclitaxel randomized pilot trial Circulation 2008 118 1358-1365.
61. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drugcoated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014; 7:10-19.
62. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357:217-227.
63. Johnson WC, Williford WO. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35:413-421.
64. Jacomella V, Corti N, Husmann M. Novel anticoagulants in the therapy of peripheral arterial and coronary artery disease. Curr Opin Pharmacol 2013; 13:294-300.